Thomas Weisel Starts Obagi Medical (OMPI) at Market Weight
More News related to OMPI
- Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
- OBAGI Medical (OMPI) Posts Q3 EPS of $0.14, In-Line with Street; Guides
- Obagi Medical Products Reports Third Quarter 2009 Earnings
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009
More News related to New Coverage
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Thomas Weisel starts Obagi Medical (Nasdaq: OMPI) at Market Weight with a $7 price target.
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.28Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
